Share Name Share Symbol Market Type Share ISIN Share Description
Doric Nimrod Air One Limited LSE:DNA London Ordinary Share GG00B4MF3899 ORD PRF SHS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 33.00 31.00 35.00 34.50 33.00 33.00 80,501 08:00:26
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -13.8 -32.4 - 14

Doric Nimrod Air One Share Discussion Threads

Showing 51 to 62 of 225 messages
Chat Pages: 9  8  7  6  5  4  3  2  1
Toshiba Corp Toshiba to enter DNA chip business next year - report TOKYO (AFX) - Toshiba Corp will enter the DNA chip market by releasing advanced chips and a chip analyzer as early as next year, the Nihon Keizai Shimbun reported at the weekend, citing sources in the company. The newspaper, in its on-line edition, said Toshiba has already developed prototypes of DNA chips designed to assess, through gene analysis, the optimum dose of rheumatism medicine for individual patients and their vulnerability to side effects, in partnership with Tokyo Women's Medical University. It has started clinical research on the chips. The company is also pushing forward, in partnership with Osaka University, with similar research on chips intended to assess tuberculosis and cancer drugs. It plans to develop a prototype of an automatic DNA chip analyzer by the end of this year. Unlike most of the DNA chips now in research use, which employ a fluorescent material to illuminate the target genes, Toshiba's prototype is designed to detect the number of genes electrically. The firm's proprietary DNA chips are more sensitive than conventional ones and offer almost 100 pct accuracy, compared to rates of 80-90 pct for regular chips, the Nikkei reported. jm
Genentech submits Biologics Licence Application for Lucentis eye drug ZURICH (AFX) - Genentech Inc., the US biotech group in which Switzerland's Roche Holding AG holds a majority stake, said it has submitted a Biologics License Application (BLA) to the US Food and Drug Administration for the use of eye drug Lucentis in the treatment of neovascular wet age-related macular degeneration. As part of the submission, the group has requested a Priority Review from the FDA, which, if okayed, would give the latter six months from the receipt of the submission to take action on the application, it said. Age-related macular degeneration (AMD) occurs in both dry and wet form. It is the number one cause of blindness for people over the age of 60. The wet form is caused by growth of abnormal blood vessels which leak fluid and blood thereby causing scar tissue that destroys the retina which results in a deterioration of sight. Lucentis, which is developed jointly by Genentech and the Novartis Ophthalmics unit, is designed to block new blood vessel growth and leaks. afx.zurich@afxnews.com ckj/jsa
grupo guitarlumber
Novartis, Roche Pfts Seen Aided By Lucentis Tuesday, November 08, 2005 5:38:23 AM ET Dow Jones Newswires 1016 GMT [Dow Jones] Genentech (DNA) and Novartis (NVS) release phase-III data for Lucentis in age-related macular degeneration. Study data showing strong efficacy should mean Lucentis can start replacing Visudyne, says Lombard Odier Darier Hentsch. Estimates worldwide sales up to $2B, around half of which would be booked by Novartis. That means Lucentis would add low single-digit net profit increase for both Novartis and - via Genentech - for Roche (RHHBY) by '10, says LODH. LODH Plans to revise estimates. Reiterates Novartis and Roche at buy, targets are CHF83 and CHF225. Novartis +0.4% at CHF71.35, Roche +1.2% at CHF197.20. http://www.newratings.com/analyst_news/article_1105368.html
Burglar kidnaps parrot A burglar abducted a parrot - fearing it would reveal his identity to police. Monty, an African Grey parrot, was the only witness as David Carlile, 32, stole antiques, jewellery and cash from an isolated country house. When he was arrested and asked why he took the bird Carlile said: "Parrots can talk and I didn't want it grassing me up." According to The Sun a police spokesman said: "We were in stitches. This guy really thought we could interview the parrot. "It's just as well we nicked him through fingerprints and DNA - I wouldn't have liked to have introduced the parrot to a judge as our chief prosecution witness. Monty remains at large after being sold. But at least Carlile is doing some bird." Carlile, of Bristol, admitted more than 100 burglaries throughout Berkshire and was jailed for seven years at Swindon Crown Court. Monty's owner Diana Winter appealed for his safe return. The seven-year-old has red feathers in his tail and a blue plastic ring on his foot. He eats only white grapes. http://www.ananova.com/news/story/sm_1603853.html?menu=
http://www.advfn.com/cmn/fbb/thread.php3?id=5876161&from=6503 Medical marketing gets 4th DNA vaccine patent; sees flu potential LONDON (AFX) - Medical Marketing International Group PLC said its Genvax unit has been granted a fourth patent for its DNA vaccines for cancer and infectious diseases, including possibly flu. Chairman David Best said the new European patent provides additional protection for technology which has "great potential in infectious diseases such as pandemic influenza as they can be rapidly developed and manufactured in response to such threats." He added that the strengthening patent portfolio "enhances our vaccine pipeline and similarly provides greater leverage to the current negotiations we are having with major pharmaceutical companies." newsdesk@afxnews.com jm/
Genentech in collaboration to explore Avastin for brain cancer treatment BURLINGAME, Calif (AFX) - Genentech Inc said it has entered into a collaboration with Accelerate Brain Cancer Cure (ABC 2), a non-profit foundation, to explore the potential of Avastin for treating patients with glioblastoma multiforme (GBM), an especially deadly form of brain cancer. The collaboration is focused on a novel imaging study of patients with recurrent GBM who are enrolled in a Phase II clinical trial at Duke University. The two parties will initially share development expenses and if the results are successful, ABC (2) will provide access to its resources for a Genentech-sponsored randomized clinical trial in relapsed GBM. "Encouraging preliminary data from early-stage research of Avastin in glioblastoma multiforme led us to initiate a Phase II study to gain further insight into Avastin's potential role in this setting," said Gwen Fyfe, Genentech's vice president of Clinical Hematology/Oncology. newsdesk@afxnews.com ak/
Roche 9-mths sales up 17 pct, narrowly beats consensus UPDATE (updates with more details on nine months sales) ZURICH (AFX) - Roche Holding AG said that nine months sales were 25.442 bln sfr, up 17 pct in local currencies, narrowly beating marketing consensus of 25.145 bln. Pharma division sales rose 20 pct, or 22 pct in local currencies, to 19.434 bln sfr, beating consensus of 19.142 bln, while sales in the Diagnostics division were up 4 pct in local currencies to 6.008 bln, in line with forecasts. The Swiss group said that sales growth in the pharma division was more than three times as fast as the global market, thanks to continued strong sales of oncology drugs -- fruits of its tie-up with Genentech Inc -- and of Tamiflu as governments stockpile for a possible flu pandemic. Oncology sales alone rose 37 pct, with sales of colorectal cancer drug Avastin up 148 pct to 1.1 bln sfr, NHL drug MabThera/Rituxan -- its top selling drug -- up 22 pct to 3.0 bln and breast cancer drug Herceptin up 38 pct to 1.4 bln. Xeloda sales were up 47 pct at 568 mln sfr, and sales of non-small cell lung cancer drug Tarceva totaled 234 mln after 11 months on the US market. In virology, Tamiflu sales rose 263 pct to 859 mln, hepatitis C and B drug Pegasys sales rose 17 pct to 1.0 bln, and anti-HIV treatment Fuzeon sales rose 49 pct to 178 mln. In anemia, the group's second biggest product NeoRecormon/Epogin saw sales rise 7 pct to 1.7 bln, and in transplantation CellCept sales rose 18 pct to 1.2 bln. afx.zurich@afxnews.com scs/hjp/jfr
Leu Ups Roche To Buy, Lifts Target To CHF210 Friday, October 14, 2005 3:37:25 AM ET Dow Jones Newswires 0718 GMT [Dow Jones] Bank Leu raises Roche (RHHBY) to buy from hold, target to CHF210 from CHF186 following strong 3Q from Genentech (DNA) and ahead of Roche's own 9 months results. "Looking into 2006 we see ample clinical and regulatory newsflow that is expected to drive the share price." Roche +0.1% at CHF184.80. (HJS) http://www.newratings.com/analyst_news/article_1063099.html
Roche to launch system for high-throughput DNA sequencing ZURICH (AFX) - Roche Holding AG said it is launching the Genome Sequencer 20 System and reagents, a technology enabling researchers to sequence genomes and long DNA sequences up to 100 times faster than current commercial platforms. The product, it said, features a nanotechnology-based approach to sequencing invented by the US-based 454 Life Sciences. Roche said its Diagnostics division will offer the Genome Sequencer 20 System and reagents and that 454 Life Sciences will continue to manufacture instrument systems and reagent kits for its Diagnostics unit. 454 Life Sciences also has the option to transfer the responsibility for reagent manufacturing to Roche Diagnostics if sales volume are sufficient. afx.zurich@afxnews.com ckj/jsa
Reading the chimp book of life By Helen Briggs BBC News science reporter Scientists have deciphered another book in the library of life - the genetic recipe of our closest living relative, the chimpanzee. It is arguably the most valuable genetic blueprint for determining what makes us human. Researchers have already begun to analyse the parts of the life code that are unique to each species. Buried within the 3 billion DNA "letters" are the changes that put our ancestors on the pathway to humanity. Wealth of new evidence It is more than a century since Charles Darwin recognised that humans and chimps are related. A wealth of evidence has emerged since then, including the discovery of the first known chimpanzee fossil revealed this week. Researchers hope the comparison of the chimp and human genomes will shed light on the past six million years or so of evolution, since the two species diverged from an apelike common ancestor. In this brief eye blink of evolutionary time, the features that make us human emerged; among them our large brain, complex speech and the ability to walk upright. At the same time, we lost many of the features we associate with our ape cousins such as their dense body hair. How are alike are we? The number of genetic differences between a mouse and a rat is about 10 times more than between a person and a chimp The number of genetic differences between a person and a chimp is about 10 times more than between two humans The number of genetic differences between a human and a chimp is about 60 times less than between a human and a mouse Alterations in the sequences of the chemical "letters" (base pairs) along our DNA should account for the differences. It turns out that we are both more and less like apes than previously thought. This apparent paradox is a hallmark of the complexity of the mammalian genome. If you take the most meaningful parts of the genome - the genes that code the proteins that build and maintain our bodies - the genetic sequences of man and ape differ by a mere 1% in terms of single letter changes to the genetic code. But in more poorly-understood parts of the genome - regions of DNA that regulate our genes, for instance, or so-called junk DNA with as yet unknown functions - we are somewhat more divergent than we once thought. Duplications and shuffling of stretches of DNA add a further difference of about 3% so, when you compare the two genomes as a whole, we share about 96% of DNA. Disease defences Many of the 35 million single letter (nucleotide) differences that set us apart from chimps lie in the genes that make proteins involved in our immune response. This is no great surprise, since chimps and humans would have encountered different diseases during evolution. Scientists decode Clint the chimp's genetic sequence Intriguingly, changes to parts of the human genome may have made us prone to certain diseases. A gene that seems to protect other animals against Alzheimer's appears not to function in our genome. Duplication of others stretches of DNA in humans are implicated in the development disorders spinal muscular atrophy and Prader-Willi syndrome. In terms of what makes us human, the most promising areas for exploration are six regions that show very little variation among humans but more variation in chimps suggesting they were important in the human line of evolution. One of these regions contains a gene called FOXP2 that seems to be important in speech. But as yet there is no smoking gun - a protein involved in regulating brain function, say - that may have caused our ape-like ancestors to branch off from chimps. With the genomes of other primates, such as the orangutan, nearing completion, there will soon be other members of the family available for comparison. The researchers who decoded the chimp genome hope that elaborating how few differences separate the species will broaden recognition of our duty to protect apes in the wild. Only a day after their study was published in the journal Nature, the UN's environment and biodiversity agencies warned that some of the great apes - chimps, gorillas, and orangutans - could be extinct in the wild within a human generation. http://news.bbc.co.uk/2/hi/science/nature/4204042.stm
Gene device slashes the cost of decoding By Nicholas Wade The New York Times TUESDAY, AUGUST 2, 2005 A new kind of machine for decoding DNA may help bring costs so low that it would be feasible to decode an individual's DNA for medical reasons. The machine, developed by a U.S.-based company, 454 Life Sciences, was used to resequence the genome of a small bacterium in four hours, its scientists report in an article published online on Monday by the journal Nature. In 1995, when the same bacterium was first sequenced, by Claire Fraser, it required 24,000 separate operations spread over four to six months, she said in an e-mail message. The machine uses the chemistry of fireflies to generate a flash of light each time a unit of DNA is correctly analyzed. The flashes from more than a million DNA-containing wells, arrayed on a plate the size of a credit card, are monitored by a light-detecting chip, the kind used in telescopes to detect the faintest light from distant stars. Then they are sent to a computer that reconstructs the sequence of the genome. The decoding or sequencing of genomes has long depended on a chemical process invented by Frederick Sanger in 1977. But genome centers based on this technology are expensive to equip and operate. For several years, biologists have been searching for a method that could be miniaturized and made cheap enough to stimulate a range of new applications. Among several promising approaches, one called pyrosequencing has been developed by Pal Nyren and Mostafa Ronaghi at the Royal Institute of Technology in Stockholm. The technique depends on separating the double helix of DNA into single strands and building up new strands to complement the old ones. As each new DNA base is added to a growing strand, a chemical component known as pyrophosphate is discarded. Nyren's team developed the chemistry to convert the discarded pyrophosphate into a trigger for luciferase, the enzyme that fireflies use to generate their light. Because the chemists knew in each cycle which of the four DNA bases they had added, a flash of light indicated the sequence at that point. Ronaghi, who is now at Stanford University, said that he and Nyren had developed the chemistry and showed it could be miniaturized and that 454 Life Sciences, having licensed their patents, had made the system practical. "What they have done here is very significant," Ronaghi said, noting that the company had already sequenced 50 microbial genomes. "This is the first step toward $1,000 human genome sequencing." The Joint Genome Institute, a federal genome sequencing center in California, has ordered one of the company's $500,000 sequencing machines but has not yet installed it. The machine's limitation is that at present it can only read DNA fragments 100 units or so in length, compared with the 800-unit reading length now attained by the Sanger-based machines. That shorter span makes it harder to reassemble all the fragments into a complete genome, said Paul Richardson of the Joint Genome Institute, so that although microbial genomes can be assembled, mammalian genomes may be beyond its reach at present. Jonathan Rothberg, chairman of 454 Life Sciences, said the company was already able to decode DNA 400 units at a time in test machines. It is working toward sequencing a human genome for $100,000, he said, adding that if costs could be further reduced to $20,000, the sequencing of individual genomes would be medically worthwhile. There would be little advantage at present in sequencing a patient's entire genome, but in the medicine of the future, complete documentation about an individual's genetic makeup could well provide a prognosis or indicate a preferred treatment. The new technology avoids a pitfall of the Sanger method, which is that the fragments of DNA to be analyzed are first amplified by being cloned in bacteria. But the bacteria cannot handle certain fragments, leaving gaps in the genome sequence. In the new technique, each fragment of DNA is captured in an individual drop of liquid and amplified to 10 million copies with a well-established chemical method known as the polymerase chain reaction. The 10 million copies from each droplet are then attached to an ultra-small bead, and the beads are dropped into a credit-card-size grid of 1.6 million wells, where the pyrosequencing takes place. Each time the correct base is added to the fragments of DNA on a specific bead, a flash of 10,000 photons is picked up through the bottom of the wells by the light-detecting chip that sits under the small grid of wells. A computer can reconstruct the sequence of bases composing the fragments and from the overlaps between fragments it can reassemble the entire genome from which they were derived. http://www.iht.com/bin/print_ipub.php?file=/articles/2005/08/01/business/dna.php
grupo guitarlumber
email print Crucial Genetics collars police deal By Julia Fields DNA testing for police investigations is to be carried out for the first time by an accredited private company in Scotland. Crucial Genetics, a spinout private firm from the University of Glasgow, will be officially accredited to undertake the tests by the United Kingdom Accreditation Service (UKAS). Based at the Southern General Hospital in Glasgow, the company expects to carry out forensic work for police forces and the military that would normally be outsourced to laboratories in England. Scientists at Crucial have already been employed by contractors known as Ã'incident response consultantsÃ" to identify victims caught up in the Iraq insurgency. Adam Middleton, business managerÊatÊCrucial,Êsaid: Ã'We've been working hard on getting this accreditation since April 2004, and it has been a long,ÊcomplicatedÊprocess. AchievingÊtheÊstandard required for UKAS accreditation is a real feather in our cap and opens up a whole new side of the business for us. Ã'We can now service police and military forensic requirements, which no other private firm in Scotland can do. In the past, if the police wanted to outsource tests to identify a murderÊvictim,ÊforÊexample, the work would generally have had to go to England, but we're now in the position where we can provide that service from Glasgow.Ã" AccordingÊtoÊMiddleton, only two other companies Ð LGC and Cellmark Ð have the same certification in the UK. Crucial Genetics was formed from a DNA profiling laboratory run by Dr John Gow for the University of Glasgow in March 2004 to reap the rewards of the technology's increasing use in areas including solving crimes and analysing animal bloodlines.ÊTheÊcompany,Êwhich stillÊbenefitsÊfromÊresearch advancements at the university, is led by chief executive Gary Hamilton and owned by the Jersey-based investment vehicle Fifty-Six Ltd. The university owns a significant share ofÊtheÊcompanyÊandÊGow remains as technical director. The company is on course to earn £200,000 in revenues by the end of 2005 from 48-hour paternity testing and tracing of family bloodlines. Middleton said: Ã'We hope that forensic analysis will significantly add to our revenues. DNA is a massive part of criminal investigation now Ð if DNA material is picked up from the scene of a crime there's a 45% chance they will be able to pick up a matching suspect from the national DNA database.Ã" CrucialÊisÊalso expanding into DNA profiling for breeding of pedigree dogs and horses. The service tests for genetic pre-disposition in the animals to produce offspring that might, for instance, have hip displasia, which leads to pain and debilitation. Ã'This has been going on in the US for a while. There are quite a lot of breeders in the UK and Ireland that might benefit from it,Ã" said Middleton. 31 July 2005 http://www.sundayherald.com/50992
grupo guitarlumber
Chat Pages: 9  8  7  6  5  4  3  2  1
ADVFN Advertorial
Your Recent History
Doric Nimr..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211020 02:43:29